Pilot Study to Evaluate the Biologic Effect of CBM588 in Combination with Nivolumab/Ipilimumab for Patients with Metastatic Renal Cell Carcinoma

Summary:

Metastatic renal cell carcinoma (mRCC) is difficult to treat, even with the encouraging combination of nivolumab and ipilimumab immunotherapy drugs. Only 42% of patients respond to this therapy, and recent studies suggest an imbalance in patient’s gut microbiome may play a role in this poor response. Dr. Pal and his team are testing adding a probiotic, CBM588, to the standard combination immunotherapy treatment in hopes that this probiotic helps to balance the gut microbiome and increase the effectiveness of the immunotherapy treatment for patients with mRCC.